Company Overview and News

 
VST Industries Limited - Updates

2018-09-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509966 VSTIND

 
VST Industries Limited - Shareholders meeting

2018-09-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509966 VSTIND

 
VST Industries Limited - AGM/Book Closure

2018-07-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509966 VSTIND

 
VST Industries Limited - Financial Result Updates

2018-07-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509966 VSTIND

 
VST Industries Limited - Trading Window

2018-07-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509966 VSTIND

4
In Pictures: A look at the richest Indians in the world

2018-04-15 moneycontrol
The number of billionaires in India has increased by 19 to 121 according to the latest annual Forbes’ Billionaires List. Indians now account for the third largest pool of billionaires in the world after the Americans and the Chinese.
500325 KMBKY RELIANCE HCTHY 530005 509966 RIGD HCLTECH KOTAKBANK VSTIND 532281 500247 INDIACEM RLNIY

 
VST Industries Limited - Updates

2018-04-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509966 VSTIND

 
Reliance Industrial, VST Ind results

2018-04-11 thehindubusinessline
Thursday will see two companies - Reliance Industrial Infrastructure and VST Industries, declaring their financial results for the quarter as well as the year ended March 2018.
509966 VSTIND RIIL 523445

 
VST Industries Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509966 VSTIND

 
VST Industries Limited - Trading Window

2018-03-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509966 VSTIND

34
Market Live: Nifty extends losses ahead of FO expiry, Sensex loses 200 pts

2018-03-28 moneycontrol
3:06 pm Persistent's FY19 Outlook: Persistent Systems clarifed that in terms of the outlook for FY 2018-19, it expects a steady growth in both revenue streams - service revenues and IP revenues.
BALKRISIND 513262 500325 ASHIANA FSL RELIANCE IDBI 539336 532859 MDCO GSPL 532612 533179 531431 509966 532121 RIGD GSK BJJQY 500676 502355 RLNIY 500034 SBAZ 532809 500116 523716 INDOCO GSKCONS HGS 532702 CPICQ 532843 GSK HINDUJAVEN GUJGAS BAJFINANCE FORTIS 500189 VSTIND DENABANK SSWL SHAKTIPUMP PERSISTENT

27
Market Live: Sensex, Nifty Bank fall over 150 pts; Alkem Labs, Persistent dip 10%

2018-03-28 moneycontrol
2:01 pm NLC Deal Called-Off: Damodar Valley Corporation has called off a deal with NLC India for acquisition of DVC's power station through JV.
BALKRISIND 513262 ASHIANA IDBI 532859 MDCO 532612 533179 531431 509966 532121 BJJQY 502355 500034 SBAZ 500116 523716 INDOCO HGS 532843 HINDUJAVEN BAJFINANCE FORTIS 500189 VSTIND DENABANK SSWL SHAKTIPUMP PERSISTENT

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...